Yin H, Wang X, Zhang X, et al. Integrated analysis of long noncoding RNA associated‐competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma. Cancer Sci. 2018;109:3336--3349. 10.1111/cas.13778

**Funding information**

This research was funded by the National Natural Science Foundation of China (81472799).

1. INTRODUCTION {#cas13778-sec-0001}
===============

Renal cancer is one of the most common malignant cancers.[1](#cas13778-bib-0001){ref-type="ref"} Despite the continuous progress in medical treatment, the incidence of the disease has increased year by year.[2](#cas13778-bib-0002){ref-type="ref"} There are many types of renal cancer according to histopathologic and cell features. Among them, clear cell renal cell carcinoma (ccRCC) is the most common type.[3](#cas13778-bib-0003){ref-type="ref"} The main and most effective treatment for ccRCC is radical nephrectomy. However, 30% of patients experience recurrence and advanced stage reduces the likelihood of survival.[4](#cas13778-bib-0004){ref-type="ref"} Moreover, regional or distant metastases leads to a high rate of death.[5](#cas13778-bib-0005){ref-type="ref"} Furthermore, ccRCC is resistant to chemotherapy and radiation therapy, so there is an urgent need to better understand the molecular mechanisms of the disease to find a new target for treatment.

Long noncoding RNA (lncRNA) are a subtype of non‐coding RNA (ncRNA) with no protein‐coding function. LncRNA are 200 nucleotides to 100 kb in length and regulate the expression of target genes transcriptionally and post‐transcriptionally.[6](#cas13778-bib-0006){ref-type="ref"} The expression of lncRNA is different in tumors compared with normal tissues and plays a key role in the development of cancers.[7](#cas13778-bib-0007){ref-type="ref"} Furthermore, lncRNA could be used as early diagnosis and prognosis cancer biomarkers due to their stronger tissue specificity.[8](#cas13778-bib-0008){ref-type="ref"} For example, in lung adenocarcinoma, lncRNA could be biomarkers for diagnosis and prognosis.[9](#cas13778-bib-0009){ref-type="ref"} MicroRNA (miRNA) are a class of small, single‐stranded, endogenous non‐coding RNA consisting of 19‐25 nucleotides that interact with the 3′‐untranslated region of the mRNA of target genes to promote mRNA degradation and/or inhibit protein translation.[10](#cas13778-bib-0010){ref-type="ref"}, [11](#cas13778-bib-0011){ref-type="ref"} Abnormal expression of miRNA can regulate the biological process by activating or inhibiting oncogenic genes, tumor suppressor genes or target proteins.[12](#cas13778-bib-0012){ref-type="ref"}, [13](#cas13778-bib-0013){ref-type="ref"}

Several recently published studies report that lncRNA can have the effect of sponging miRNA, which weakens the impact of miRNA on mRNA according to the theories about RNA regulation by competitive endogenous RNA (ceRNA).[14](#cas13778-bib-0014){ref-type="ref"}, [15](#cas13778-bib-0015){ref-type="ref"} The primary theory is that RNA could interact with miRNA response elements (MRE).[16](#cas13778-bib-0016){ref-type="ref"} Then, different genes compete for the identical miRNA, which forms a complex network of RNA regulation, thus affecting pathway and function.[17](#cas13778-bib-0017){ref-type="ref"} In a study of hepatocellular cell carcinoma, Zhang explored lncRNA profiles and constructed an lncRNA‐miRNA‐mRNA network.[18](#cas13778-bib-0018){ref-type="ref"} In addition, Xue et al constructed a ceRNA network of esophageal cancer.[19](#cas13778-bib-0019){ref-type="ref"} In papillary renal cell carcinoma, a ceRNA network was also constructed.[20](#cas13778-bib-0020){ref-type="ref"} However, studies of large‐scale samples and microarray detection in ccRCC are still rare and the relationship between lncRNA and prognosis is unclear and urgently needs to be defined. Therefore, the construction of a ceRNA network has an important role in therapeutic decisions, prognosis prediction and therapeutic targeting to improve the overall survival of ccRCC patients.

In the present study, we obtained the lncRNA, miRNA and mRNA expression profiles of ccRCC normal tissue and tumor tissue from The Cancer Genome Atlas (TCGA). Furthermore, an lncRNA‐miRNA‐mRNA ceRNA network was constructed for ccRCC through integrated analysis, which can help in finding new targets and pathways to improve survival for patients. Finally, we put significant lncRNA into a prognosis analysis and found biomarkers to predict survival in ccRCC.

2. MATERIALS AND METHODS {#cas13778-sec-0002}
========================

2.1. Data collection {#cas13778-sec-0003}
--------------------

The clinical data for age, sex and TNM stage were obtained from the TCGA database (2018.04.01). The exclusion criteria were that: (i) the histological diagnosis was not ccRCC; and (ii) there was not enough information for clinical characteristics (including age, gender, stage, survival status and survival time). Altogether, there were 519 ccRCC patients enrolled in the study. The numbers of stage I, II, III and IV patients were 263, 55, 119 and 82, respectively. In addition, 17 patients had received neoadjuvant treatment; the others had not. The number of patients aged \<62 years was 277, and the other 242 patients were ≥62 years old. A total of 335 patients were male, and the other 184 patients were female. The number of ccRCC with tumor grades 1, 2, 3 and 4 were 14 (2.7%), 225 (43.4%), 206 (39.7%) and 74 (14.3%), respectively. Furthermore, the numbers of patients who were Asian, black or African American, white and not available were 8, 52, 452 and 7, respectively. Level 3 RNA expression data were collected from the TCGA Data Portal and normalized.[21](#cas13778-bib-0021){ref-type="ref"}

2.2. Explore the differentially expressed genes {#cas13778-sec-0004}
-----------------------------------------------

The RNA sequencing (RNA‐Seq) data were derived from the TCGA data portal. There are 539 ccRCC tumor tissues and 72 adjacent normal tissues with available mRNASeq and lncRNASeq. Furthermore, there are 545 ccRCC tumor tissues and 71 adjacent normal tissues with available miRNASeq. We used the R and Bioconductor package of edgeR to explore the significantly differentially expressed mRNA (DEmiRNA), lncRNA (DElncRNA) and miRNA (DEmRNA) between cancer tissues and normal tissues.[22](#cas13778-bib-0022){ref-type="ref"} The genes that were not registered in GENCODE were abandoned to maximize data reliability. The cut‐off value was \|log2FC\| \> 2 and FDR* *\<* *.01 (FC, fold change; FDR, false discovery rate).

2.3. Construct the competitive endogenous RNA network {#cas13778-sec-0005}
-----------------------------------------------------

We constructed the network based on the network among lncRNA, miRNA and mRNA. The interaction between lncRNA and miRNA or mRNA and miRNA could be predicted. Therefore, we used miRcode (<http://www.mircode.org/>) to predict lncRNA and miRNA interactions. Then, miRDB (<http://www.mirdb.org/>), TargetScan (<http://www.targetscan.org/vert_71/>) and miRanda (<http://www.targetscan.org/vert/>) databases were used to predict miRNA and mRNA interactions. The interactions of results were used to construct the lncRNA‐miRNA‐mRNA network applying the Cytoscape software.[23](#cas13778-bib-0023){ref-type="ref"}

2.4. Function and pathway enrichment {#cas13778-sec-0006}
------------------------------------

To better understand the underlying function of aberrantly expressed genes, the gene ontology (GO) was needed. Therefore, we used the Database for Annotation Visualization and Integrated Discovery 6.8 (DAVID) (<https://david.ncifcrf.gov/>) to perform the functional analyses.[24](#cas13778-bib-0024){ref-type="ref"} Then, we used KOBAS 3.0 (<http://kobas.cbi.pku.edu.cn/anno_iden.php>) to construct Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.[25](#cas13778-bib-0025){ref-type="ref"}

2.5. Identification and selection of prognosis‐related lncRNA in the training set {#cas13778-sec-0007}
---------------------------------------------------------------------------------

All 519 patients were randomly grouped into a training set (n = 259) and a testing set (n = 260; as shown in Table [1](#cas13778-tbl-0001){ref-type="table"}). We used the univariate Cox proportional hazards regression to explore the differentially expressed lncRNA and estimated the expression of lncRNA with overall survival (OS) by R with the survival package. Then, we identified some lncRNA whose expression is significantly correlated with OS in univariate Cox proportional hazards regression analysis, which were used for multivariate analysis. We calculated the prognostic risk score as exp~lncRNA1~ \* β~lncRNA1~ + exp~lncRNA2~ \* β~lncRNA2~ + exp~lncRNAn~ \* β~lncRNAn~ (exp, expression level, β, the regression coefficient derived from the multivariate Cox regression model).[26](#cas13778-bib-0026){ref-type="ref"} The median risk score was 1.087797. All the patients were divided into low‐risk and high‐risk groups based on the median risk score. Kaplan‐Meier survival curves were further used to calculate the OS of the different risk groups. A time‐dependent receiver operating characteristic (ROC) curve analysis with 5 years as the defining point was performed with the R package "survival‐ROC" to evaluate the predictive value of the risk score.[27](#cas13778-bib-0027){ref-type="ref"}

###### 

519 clear cell renal cell carcinoma patient characteristics and clinical data

  Characteristics             Entire dataset *N* (%)   Training dataset *N* (%)   Testing dataset *N* (%)   *P*
  --------------------------- ------------------------ -------------------------- ------------------------- ------
  *N*                         519                      259 (49.9)                 260 (50.1)                
  Age (year) (mean ± SD)      61.03 ± 12.17                                                                 
  \<62                        277 (53.4)               141 (54.4)                 136 (52.3)                .626
  ≧62                         242 (46.6)               118 (45.6)                 124 (47.7)                
  Sex                                                                                                       
  Male                        335 (64.5)               167 (64.5)                 168 (64.6)                .974
  Female                      184 (35.5)               92 (35.5)                  92 (33.4)                 
  Race                                                                                                      
  Asian                       8 (1.5)                  3 (1.2)                    5 (1.9)                   .704
  Black or African American   52 (10.0)                28 (10.8)                  24 (9.2)                  
  White                       452 (87.1)               223 (86.1)                 229 (88.1)                
  Not available               7 (1.3)                  5 (1.9)                    2 (1)                     
  Neoadjuvant treatment                                                                                     
  Yes                         17 (3.3)                 6 (2.3)                    11 (4)                    .221
  No                          502 (96.7)               253 (97.7)                 249 (95.8)                
  Tumor grade                                                                                               
  1                           14 (2.7)                 8 (3.1)                    6 (2.3)                   .917
  2                           225 (43.4)               117 (45.2)                 108 (41.5)                
  3                           206 (39.7)               97 (37.5)                  99 (38.1)                 
  4                           74 (14.3)                37 (14.3)                  37 (14.2)                 
  Tumor stage                                                                                               
  I                           263 (50.7)               133 (51.4)                 130 (50)                  .45
  II                          55 (10.6)                22 (8.5)                   33 (12.7)                 
  III                         119 (22.9)               63 (24.3)                  56 (21.5)                 
  IV                          82 (15.8)                41 (15.8)                  41 (15.8)                 
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2.6. The prognostic lncRNA in the testing and the entire dataset {#cas13778-sec-0008}
----------------------------------------------------------------

The prognostic lncRNA in the training set were further explored in the testing and entire dataset. Patients were also divided into high‐risk and low‐risk groups according to the risk score. The ROC curve and survival were analyzed in the 2 datasets.

2.7. The prognostic factors of clinical features {#cas13778-sec-0009}
------------------------------------------------

We carried out the univariate Cox regression analysis between clinical features (age, gender, race, neoadjuvant treatment, the histologic grade, the pathologic stage and the risk) and OS using SPSS 22.0 software. The significant value was further explored in the multivariate Cox regression analysis.

2.8. Statistical analysis {#cas13778-sec-0010}
-------------------------

An unpaired *t* test was used to identify differentially expressed genes between tumor tissues and normal tissues. To further identify the gene associated‐competing endogenous RNA, we combined the clinical data of ccRCC patients. The survival package in R was used to plot the survival curves.

3. RESULTS {#cas13778-sec-0011}
==========

3.1. Clinical characteristics of clear cell renal cell carcinoma patients {#cas13778-sec-0012}
-------------------------------------------------------------------------

There were 519 tumor patients enrolled in the study. The mean age of all the patients was 61.03 ± 12.17. The number of patients aged \<62 years was 277, and the other 242 patients were ≥62 years old. A total of 335 patients were male, and the other 184 patients were female. The number of ccRCC with tumor grades 1, 2, 3 and 4 were 14 (2.7%), 225 (43.4%), 206 (39.7%) and 74 (14.3%), respectively. A total of 17 patients underwent neoadjuvant therapy; the others did not. In addition, the number of tumors of TNM stage I, II, III and IV were 263 (50.7%), 55 (10.6%), 119 (22.9%) and 82 (15.8%), respectively. All the patients were randomly divided into the training set and the testing set. There was no correlation between the 2 groups (*P *\>* *.05). The results are listed in Table [1](#cas13778-tbl-0001){ref-type="table"}.

3.2. Differentially expressed lncRNA, miRNA and mRNA {#cas13778-sec-0013}
----------------------------------------------------

The differential expression (DE) of mRNA and lncRNA between tumor tissues and normal tissues was explored. Absolute fold change \>2 and FDR value \<.01 of genes were considered as discriminatively expressed. The analysis identified 2331 mRNA (1569 elevated and 762 downregulated; Figure [1](#cas13778-fig-0001){ref-type="fig"}A) and 1518 lncRNA (1059 elevated and 459 downregulated; Figure [1](#cas13778-fig-0001){ref-type="fig"}B). Filtering analysis with the above criteria (absolute fold change \>2 and FDR value \<.01) identified 54 miRNA (33 elevated and 21 downregulated; Figure [1](#cas13778-fig-0001){ref-type="fig"}C) between normal tissues and cancer tissues. The results suggested that the expression of these genes can distinguish ccRCC from normal tissues.

![Heatmap and volcano map of the differential expression of genes in clear cell renal cell carcinoma (ccRCC) between 519 tumor tissues and 72 normal tissues. Ascending normalized expression level is colored from green to red. A, mRNA; B, lncRNA; C, miRNA](CAS-109-3336-g001){#cas13778-fig-0001}

3.3. Competitive endogenous RNA network in clear cell renal cell carcinoma {#cas13778-sec-0014}
--------------------------------------------------------------------------

Next, the potential interactions among the above genes were predicted according to the ceRNA hypothesis. A total of 89 DElncRNA were predicted to interact with 10 DEmiRNA by miRcode online tools (Table [S1](#cas13778-sup-0001){ref-type="supplementary-material"}). Furthermore, we combined miRDB, TargetScan and miRanda to predict the candidate mRNA targets of DEmiRNA (Table [2](#cas13778-tbl-0002){ref-type="table"}). The 22 target DEmRNA that were also involved in the 2331 differential mRNA were enrolled in the ceRNA network (Figure [2](#cas13778-fig-0002){ref-type="fig"}). In total, there were 89 DElncRNA, 10 DEmiRNA and 22 DEmRNA in the ceRNA network. Furthermore, Cytoscape software was used to construct the interactions among DElncRNA, DEmiRNA and DEmRNA (Figure [3](#cas13778-fig-0003){ref-type="fig"}).

###### 

MiRNA that may target mRNA in clear cell renal cell carcinoma

  miRNA      mRNA
  ---------- --------------------------------------------------
  miR‐200c   NTRK2,NOG,LRP1B,GATA4,ERMP1,VEGFA
  miR‐122    GALNT3
  miR‐155    PCDH9,GPM6B,ITK,ZNF98,TYRP1,CD36,ZIC3,SPI1,ERMP1
  miR‐216b   COL4A4
  miR‐506    SLC16A1,VIM
  miR‐141    PRELID2
  miR‐21     CCL20,TGFBI,FASLG
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![The 22 target DEmRNA that were also involved in the 2331 different mRNA were enrolled in the ceRNA network](CAS-109-3336-g002){#cas13778-fig-0002}

![The lncRNA‐miRNA‐mRNA ceRNA network. The blue diamonds are downregulated lncRNAand the red diamonds are upregulated lncRNA. The blue rectangles are downregulated miRNA and the red rectangles are upregulated miRNA. The blue balls are downregulated mRNAand the red balls are upregulated mRNA](CAS-109-3336-g003){#cas13778-fig-0003}

3.4. DEmRNA in the competitive endogenous RNA network {#cas13778-sec-0015}
-----------------------------------------------------

The functions and KEGG pathways of 22 DEmRNA in the ceRNA network were analyzed with DAVID and KOBAS. The results showed 4 GO terms (*P *\<* *.01) and 13 KEGG pathways (corrected *P*‐value \< .05). The results of GO terms are shown in Table [3](#cas13778-tbl-0003){ref-type="table"} and Figure [4](#cas13778-fig-0004){ref-type="fig"}. The KEGG pathways of DEmRNA are shown in Table [4](#cas13778-tbl-0004){ref-type="table"}. Furthermore, we imported the above data into Cytoscape to calculate the characteristics of the network (Figure [5](#cas13778-fig-0005){ref-type="fig"}). Next, the relationship between the 22 DEmRNA and OS was also explored. The results showed that patients with high expression of COL4A4, ERMP1 and PRELID2 had a better OS (*P *\<* *.05). In addition, patients with low expression of NOG, SPI1, TGFβ1, TYRP1 and VIM had better OS (*P *\<* *.05; Figure [6](#cas13778-fig-0006){ref-type="fig"}).

###### 

GO terms of DEmRNA in clear cell renal cell carcinoma

  ID           Term                                     Genes                               Count   *P*
  ------------ ---------------------------------------- ----------------------------------- ------- ------------
  GO:0035019   Stem cell population maintenance         NOG, SPI1, ZIC3                     3       .002954723
  GO:0010628   Positive regulation of gene expression   NOG, VIM, VEGFA, NTRK2              4       .004056413
  GO:0051525   NFAT protein binding                     GATA4, SPI1                         2       .005910498
  GO:0042803   Protein homodimerization activity        SLC16A1, TYRP1, NOG, VEGFA, NTRK2   5       .009660452
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![The functions of DEmRNAin the ceRNA network were analyzed with DAVID. A, GO enrichment significance items of DEmRNA in different functional groups. B and C, Distribution of DEmRNA in clear cell renal cell carcinoma (ccRCC) for different GO‐enriched functions. DEmRNA, differentially expressed mRNA;GO, gene ontology](CAS-109-3336-g004){#cas13778-fig-0004}

###### 

KEGG pathway of DEmRNA in clear cell renal cell carcinoma

  ID         Term                                                   Genes                     Count   Corrected *P*‐value
  ---------- ------------------------------------------------------ ------------------------- ------- ---------------------
  hsa05200   Pathways in cancer                                     COL4A4,VEGFA,SPI1,FASLG   4       .00405917615921
  hsa04060   Cytokine‐cytokine receptor interaction                 CCL20,VEGFA,FASLG         3       .0133388641347
  hsa04151   PI3K‐Akt signaling pathway                             VEGFA,COL4A4,FASLG        3       .005910498
  hsa04512   ECM‐receptor interaction                               COL4A4,CD36               2       .009660452
  hsa05323   Rheumatoid arthritis                                   CCL20,VEGFA               2       .015264
  hsa04933   AGE‐RAGE signaling pathway in diabetic complications   COL4A4,VEGFA              2       .015566
  hsa04722   Neurotrophin signaling pathway                         NTRK2,FASLG               2       .018629
  hsa04062   Chemokine signaling pathway                            CCL20,ITK                 2       .033286
  hsa04510   Focal adhesion                                         COL4A4,VEGFA              2       .033286
  hsa05169   Epstein‐Barr virus infection                           SPI1,VIM                  2       .033286
  hsa05205   Proteoglycans in cancer                                FASLG,VEGFA               2       .033286
  hsa04014   Ras signaling pathway                                  FASLG,VEGFA               2       .0374
  hsa04010   MAPK signaling pathway                                 FASLG,NTRK2               2       .042737

John Wiley & Sons, Ltd

![Signifcant pathway enrichment of DEmRNA. Red represents the upregulated DEmRNA. Green represents the downregulated DEmRNA. Blue represents signaling pathway. DEmRNA, differentially expressed mRNA](CAS-109-3336-g005){#cas13778-fig-0005}

![The results showed the patients with high expression of COL4A4, ERMP1 and PRELID2 had a better overall survival (OS) (*P *\<* *.05). In contrast, patients with low expression of NOG,SPI1, TGFβ1, TYRP1 and VIM had better overall survival (*P *\<* *.05). (![](CAS-109-3336-g012.jpg "image") ![](CAS-109-3336-g013.jpg "image")) High expression.](CAS-109-3336-g006){#cas13778-fig-0006}

3.5. DElncRNA in relation to overall survival in the training set {#cas13778-sec-0016}
-----------------------------------------------------------------

To further analyze the function of DElncRNA, we calculated the relationship between the 89 DElncRNA in the network and overall survival using the Cox proportional hazards regression model in the training set. The results showed that 22 DElncRNA were closely related with overall survival in the univariate analysis (*P *\<* *.01). Then, the 22 DElncRNA were analyzed by multivariate Cox regression. The results showed 9 DElncRNA, SLC25A5‐AS1, COL18A1‐AS1, WT1‐AS, AC016773.1, LINC00460, LINC00313, HOTTIP, FGF14‐AS1 and AC105020.1 to be independent influencing factors of survival time (*P *\<* *.001; Table [5](#cas13778-tbl-0005){ref-type="table"}). The risk score was imputed as follows: the expression of SLC25A5‐AS1 \* (−.005539) + the expression of COL18A1‐AS1 \* (−.011813) + the expression of WT1‐AS \* .005503 + the expression of AC016773.1 \* .014487 + the expression of LINC00460 \* .001143 + the expression of LINC00313 \* .015264 + the expression of HOTTIP \* .008013 + the expression of FGF14‐AS1 \* (−.193023) + the expression of AC105020.1 \* .001524. Among the 9 lncRNA, the coefficients in Cox regression of SLC25A5‐AS1, COL18A1‐AS1 and FGF14‐AS1 were negative. In contrast, the coefficients in the Cox regression of WT1‐AS, AC016773.1, LINC00460, LINC00313, HOTTIP and AC105020.1 were positive.

###### 

Multivarite analysis of DElncRNA for overall survival

  Gene          Ensembl ID        Coefficient   Exp (coefficient)   SE (coefficient)   *Z*     *P*
  ------------- ----------------- ------------- ------------------- ------------------ ------- --------
  SLC25A5‐AS1   ENSG00000224281   −.005539      .994476             .003704            −1.50   .13481
  COL18A1‐AS1   ENSG00000183535   −.011813      .988257             .007592            −1.56   .11973
  WT1‐AS        ENSG00000183242   .005503       1.005518            .002349            2.34    .01915
  AC016773.1    ENSG00000270195   .014487       1.014592            .003947            3.67    .00024
  LINC00460     ENSG00000233532   .001143       1.001144            .000679            1.68    .09203
  LINC00313     ENSG00000185186   .015264       1.015381            .008925            1.71    .08723
  HOTTIP        ENSG00000243766   .008013       1.008045            .004220            1.90    .05762
  FGF14‐AS1     ENSG00000234445   −.193023      .824463             .109902            −1.76   .07903
  AC10502.1     ENSG00000203392   .001524       1.001525            .000806            1.89    .05871
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Next, we calculated the 9 lncRNA expression‐based survival risk score of the 259 patients. The median risk score was 1.087797. All the patients were divided into low‐risk and high‐risk groups based on the median risk score. The survival of 2 different groups was calculated using Kaplan‐Meier curves, and the results showed that the risk was closed correlated with OS. Patients with high‐risk scores had poorer OS than patients with low‐risk scores (*P *\<* *.001; Figure [7](#cas13778-fig-0007){ref-type="fig"}A). The 5‐year OS of the low‐risk and high‐risk groups were 86.7 (95%CI = .798‐.943) and 42.9 (95%CI = .3377‐.546), respectively. Furthermore, we evaluated the 9‐lncRNA signature using the area under ROC curve (AUC) of the ROC curve. The result showed that the value of AUC was .786 (Figure [7](#cas13778-fig-0007){ref-type="fig"}B). The distributions of the risk score, survival state and expression of 9 lncRNA in the training set are shown in Figure [7](#cas13778-fig-0007){ref-type="fig"}C.

![Identification and performance evaluation of the 9‐lncRNA signature in the training dataset. A, Kaplan‐Meier survival curve analysis for overall survival of clear cell renal cell carcinoma patients using the 9‐lncRNA signature in the training dataset; B, ROC curve analysis of the 9‐lncRNA signature in the training dataset; C, The distributions of the RSlncRNA, survival status and expression profiles of the 9 lncRNAof patients in the training dataset](CAS-109-3336-g007){#cas13778-fig-0007}

3.6. The 9‐lncRNA signature for survival prediction in the testing and the entire set {#cas13778-sec-0017}
-------------------------------------------------------------------------------------

Next, to further evaluate the 9‐lncRNA signature for survival prediction in ccRCC patients, we tested it in the testing and entire sets. The predictive model and cut‐off point used were the same as for the training set. The testing set was divided into a low‐risk group (n = 131) and a high‐risk group (n = 129). The survival of the 2 risk groups was calculated by Kaplan‐Meier survival curves as in the training set. Patients with high‐risk scores had poorer OS than patients with low‐risk scores (*P *\<* *.001, Figure [8](#cas13778-fig-0008){ref-type="fig"}A). The 5‐year OS of the low‐risk and high‐risk groups were 82.1 (95%CI = .747‐.902) and 45.9 (95%CI = .369‐.57), respectively. The AUC in the ROC curve was .722 (Figure [8](#cas13778-fig-0008){ref-type="fig"}B). The distributions of the risk score, survival state and expression of 9 lncRNA in the testing set are shown in Figure [8](#cas13778-fig-0008){ref-type="fig"}C.

![Evaluation of the 9‐lncRNA signature in the testing dataset. A, Kaplan‐Meier survival curve analysis for overall survival of clear cell renal cell carcinoma patients using the 9‐lncRNA signature in the testing dataset; B, receiver operating characteristic curve analysis of the 9‐lncRNA signature in the testing dataset; C, the distributions of the RSlncRNA, survival status and expression profiles of the 9 lncRNA of patients in the testing dataset](CAS-109-3336-g008){#cas13778-fig-0008}

The results for the entire set were similar. The patients with high‐risk scores had poorer OS than patients with low‐risk scores (*P *\<* *.001; Figure [9](#cas13778-fig-0009){ref-type="fig"}A). The 5‐year OS of the low‐risk and high‐risk groups were 83.3 (95%CI = .779‐.89) and 48 (95%CI = .415‐.555), respectively. The AUC in the ROC curve was .74 (Figure [9](#cas13778-fig-0009){ref-type="fig"}B). The distributions of the risk score, survival state and expression of 9 lncRNA in the entire set are shown in Figure [9](#cas13778-fig-0009){ref-type="fig"}C.

![Evaluation of the 9‐lncRNA signature in the entire dataset. A, Kaplan‐Meier survival curve analysis for overall survival of clear cell renal cell carcinoma patients using the 9‐lncRNA signature in the entire dataset; B, receiver operating characteristic curve analysis of the 9‐lncRNA signature in the entire dataset; C, the distributions of the RSlncRNA, survival status and expression profiles of the 9 lncRNAof patients in the entire dataset](CAS-109-3336-g009){#cas13778-fig-0009}

3.7. The prognostic factors of clinical features {#cas13778-sec-0018}
------------------------------------------------

The clinical factors of 519 ccRCC patients were further evaluated using SPSS 22 software. The univariate Cox regression analysis showed that age, neoadjuvant treatment, histologic grade, pathologic stage and risk were factors affecting survival. However, in the multivariate COX regression analysis, age, histologic grade, pathologic stage and risk were independent prognostic indictors in ccRCC (Table [6](#cas13778-tbl-0006){ref-type="table"}). The survival curves were drawn using the Kaplan‐Meier method, and the factors age, histologic grade, pathologic stage and risk were associated with OS (*P *=* *.001, \<.001, \<.001 and \<.001; Figure [10](#cas13778-fig-0010){ref-type="fig"}). Furthermore, age, histologic grade and pathologic stage were also significant risk factors affecting survival. Therefore, we undertook a stratification analysis to further explore the signature of the 9 lncRNA within the same clinical factor.

###### 

519 patients characteristics and clinical data

  Characteristic              Value (%)    Univariate            Multivariate                         
  --------------------------- ------------ --------------------- -------------- --------------------- --------
  Age, years (mean ± SD)                                                                              
  \<62                        277 (53.4)                                                              
  ≧62                         242 (46.6)   1.707 (1.258‐2.316)   .001           1.475 (1.086‐2.004)   .013
  Sex                                                                                                 
  Male                        335 (64.5)                                                              
  Female                      184 (35.5)   .962 (.704‐1.314)     .809                                 
  Neoadjuvant treatment                                                                               
  Yes                         17 (3.3)                                                                
  No                          502 (96.7)   .468 (.247‐.888)      .02            .565 (.296‐1.078)     .083
  Race                                                                                                
  Asian                       8 (1.5)                                                                 
  Black or African American   52 (10.0)                                                               
  White                       452 (87.1)                                                              
  Not available               7 (1.3)      1.075 (.819‐1.411)    .604                                 
  Grade                                                                                               
  1‐2                         239 (46.1)                                                              
  3‐4                         280 (53.9)   2.643 (1.875‐3.725)   \<.001         1.703 (1.186‐2.446)   .004
  Tumor stage                                                                                         
  I + II                      318 (61.3)                                                              
  III + IV                    201 (38.7)   3.741 (2.721‐5.143)   \<.001         2.486 (1.771‐3.49)    \<.001
  Risk                                                                                                
  Low‐risk                    247 (47.6)                                                              
  High‐risk                   272 (52.4)   3.995 (2.762‐5.777)   \<.001         2.953 (2.021‐4.315)   \<.001

John Wiley & Sons, Ltd

![The prognostic value of different clinical features for overall survival of clear cell renal cell carcinoma patients. Kaplan‐Meier curves of 3 independent prognostic indictors](CAS-109-3336-g010){#cas13778-fig-0010}

First, we placed all 519 patients into a younger group (age \< 62; n = 277) or an older group (age \> 62; n = 242). The log‐rank test result showed that the low‐risk patients (n = 136) had a better OS than high‐risk (n = 141) patients in the younger group (*P *\<* *.001). The result in the older group was similar (Figure [11](#cas13778-fig-0011){ref-type="fig"}A). The low‐risk patients (n = 111) had a better OS than the high‐risk patients (n = 131; *P *\<* *.001). Then, the patients were divided into an early stage (I + II; n = 315) group and a late‐stage (III + IV) group. In the early stage group, the low‐risk patients (n = 184) had a better OS than the high‐risk patients (n = 131; *P *\<* *.001). In the late‐stage group, the result was similar (*P *\<* *.001; Figure [11](#cas13778-fig-0011){ref-type="fig"}B). Finally, we placed patients into a low‐grade group (n = 239) or a high‐grade group (n = 280). In the low‐grade group, the low‐risk patients (n = 141) had a better OS than the high‐risk patients (n = 98; *P *\<* *.001). In the high‐grade group, the result was similar (*P *\<* *.001; Figure [11](#cas13778-fig-0011){ref-type="fig"}C).

![Kaplan‐Meier survival curve analysis for overall survival of patients stratified by age, stage and grade using the 9‐lncRNA signature in the entire dataset. A, Kaplan‐Meier survival curves of the younger patients group; B, Kaplan‐Meier survival curves of the older patient group; C, Kaplan‐Meier survival curves of the early stage patients group; D, Kaplan‐Meier survival curves of the late‐stage patients group; E, Kaplan‐Meier survival curves of the low‐grade patients group; F, Kaplan‐Meier survival curves of the high‐grade patients group](CAS-109-3336-g011){#cas13778-fig-0011}

4. DISCUSSION {#cas13778-sec-0019}
=============

Renal cell carcinoma is one of the most common malignant carcinomas in the world and has a high incidence and mortality rate.[28](#cas13778-bib-0028){ref-type="ref"} In a previous study, we identified biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co‐expression network analysis.[29](#cas13778-bib-0029){ref-type="ref"} CcRCC is the most common type of renal cancer, and there is an urgent need to explore the mechanism of the disease. LncRNA play important roles in tumor progression and may be biomarkers for clinical diagnosis and prognosis according to recent studies. For example, in colorectal cancer, the lncRNA AB073614 induced epithelial mesenchymal transition.[30](#cas13778-bib-0030){ref-type="ref"} In cervical cancer, lncRNA SNHG20 promoted cell proliferation and invasion.[31](#cas13778-bib-0031){ref-type="ref"}

Furthermore, lncRNA were able to compete with mRNA for the binding sites of miRNA which affect the expression of mRNA through MRE. For example, the lncRNA UICLM acted as a ceRNA for miR‐215 to regulate ZEB2 expression in colorectal cancer.[32](#cas13778-bib-0032){ref-type="ref"} In gastric cancer, the lncRNA BC0032469 upregulated hTERT expression by sponging miR‐1207, which promoted proliferation.[33](#cas13778-bib-0033){ref-type="ref"} In hepatocellular cancer, the lncRNA SNHG6‐003 also functions as a ceRNA to promote tumor progression.[34](#cas13778-bib-0034){ref-type="ref"} Therefore, constructing a ceRNA network is important to explore the mechanism of the disease.

There are many studies on ceRNA networks in numerous cancers; however, few of them are on ccRCC. In addition, the sample sizes have not been large enough. Therefore, in the present study, we explored the interactions among lncRNA, miRNA and mRNA by constructing a ceRNA network in ccRCC by means of TCGA databases. First, we identified differentially expressed mRNA, lncRNA and miRNA between tumor tissues and normal tissues. Then, using bioinformatics tools, we explored 89 DElncRNA, 10 DEmiRNA and 22 DEmRNA and constructed a ceRNA network. Furthermore, we analyzed the GO functions and KEGG pathways of 22 DEmRNA. The GO enrichment results revealed that the main functions are stem cell population maintenance, positive regulation of gene expression, NFAT protein binding and protein homodimerization activity. The KEGG pathway enrichment results identified that pathways in cancer, cytokine receptor interaction and PI3K‐Akt signaling pathways are the main affected pathways. In rectal cancer, the main DEmRNA‐associated pathways were PI3K‐Akt, WNT, AMPK and cGMP‐PKG signaling pathways, as well as cell adhesion molecules. In thyroid cancer, the main pathways were pathways in cancer and cytokine receptor interaction. Therefore, the ceRNA network played an important role in the cancer progression.

LncRNA played a vital role in cancer and could be used to predict the survival prognosis. The lncRNA FMO6P and PRR26 were identified to construct a risk score to predict the prognostic value in lung cancer.[35](#cas13778-bib-0035){ref-type="ref"} In pancreatic ductal adenocarcinoma, a 5‐lncRNA signature (C9orf139, MIR600HG, RP5‐965G21.4, RP11‐436K8.1 and CTC‐327F10.4) could be used to make prognoses for patients.[36](#cas13778-bib-0036){ref-type="ref"} In ER‐positive breast cancer, a 6‐lncRNA (HAGLR, STK4‐AS1, DLEU7‐AS1, LINC00957, LINC01614 and ITPR1‐AS1) signature was a potential prognostic marker for survival prediction.[37](#cas13778-bib-0037){ref-type="ref"} In esophageal squamous cell cancer, a 3‐lncRNA signature could predict overall survival.[38](#cas13778-bib-0038){ref-type="ref"} In our study, we explored the correlation between survival and 89 DElncRNA in the training dataset. The 9 lncRNA, SLC25A5‐AS1, COL18A1‐AS1, WT1‐AS, AC016773.1, LINC00460, LINC00313, HOTTIP, FGF14‐AS1 and AC105020.1, showed a significant prognostic value for the survival of ccRCC patients by multivariate Cox proportional hazards regression analysis. Then, we explored the risk score by combining the 9 lncRNA and found that this 9‐lncRNA signature independently predicted survival in ccRCC patients. The 9 lncRNA were further proved in the testing group and the entire group, which demonstrated good reproducibility. Furthermore, multivariate Cox regression and further analysis proved that the 9‐lncRNA signature was an independent prognostic factor to predict survival in ccRCC patients. Specifically, to our knowledge, this is the first study combining a ceRNA network constructed by TCGA databases and constructing an lncRNA risk score in ccRCC.

However, there are several limitations to our study. The main method in our study was bioinformatics technology, which appears as a promising tool to understand the function of gene and protein interactions, pathways and networks. However, the functions and networks of lncRNA are complex. In our study, the network was constructed only by means of the ceRNA theory. Moreover, a longer follow‐up is needed to validate our findings. Finally, other databases still need to be used to verify the findings.

In conclusion, our study performed a comprehensive analysis of mRNA, miRNA and lncRNA expression profiles and clinical data of ccRCC patients in the TCGA database. We constructed a ceRNA network and identified a 9‐lncRNA signature that is closely associated with overall survival to predict prognosis. The 9 lncRNA were further proved to predict the survival risk in the testing and entire sets. Furthermore, multivariate analysis proved the 9‐lncRNA signature to be an independent factor affecting survival and other clinical factors. Therefore, the current study not only provided the ceRNA molecular mechanisms, but also explored the potential of a novel 9‐lncRNA signature as a candidate biomarker for ccRCC patients.
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